# Arcus Biosciences, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Arcus Biosciences, Inc.).

## Overview

Arcus Biosciences is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and, to a lesser extent, inflammatory and autoimmune diseases. The company does not sell commercial products today; instead, it advances a pipeline of investigational antibodies and combination regimens through partnerships with larger pharmaceutical companies. Its business model is built around R&D execution, collaboration revenue, and milestone/option economics rather than product sales. Arcus is headquartered in Hayward, California and operates as a single reportable segment. The company relies heavily on third-party manufacturers and collaborators to fund, de-risk, and help advance its programs.

## Products & services

• Domvanalimab anti-TIGIT antibody program
• Quemliclustat adenosine-pathway program
• Etrumadenant adenosine receptor antagonist program
• Casdatifan HIF-2α inhibitor program
• Research, collaboration and license arrangements
• Clinical development services for partnered programs

- **Oncology immunotherapy pipeline** (70%) — Investigational cancer therapies including anti-TIGIT, adenosine-pathway and HIF-2α programs developed for solid tumors.
- **Collaborative R&D services** (25%) — Development work performed under collaboration agreements where revenue is recognized over time as obligations are satisfied.
- **License and option arrangements** (5%) — Upfront, milestone and option-related consideration from partners such as Gilead, Taiho and AstraZeneca.

- Domvanalimab anti-TIGIT antibody program
- Quemliclustat adenosine-pathway program
- Etrumadenant adenosine receptor antagonist program
- Casdatifan HIF-2α inhibitor program
- Research, collaboration and license arrangements
- Clinical development services for partnered programs

## Customers

Arcus does not have traditional end customers for product sales; its revenue comes from strategic pharmaceutical partners that fund or co-develop its pipeline. Gilead is the most important collaborator and equity partner, while Taiho and AstraZeneca also support specific programs through license, option or clinical collaboration structures. These partners buy access to Arcus’s scientific platform, rights to specific assets, and the ability to share development risk in oncology programs. In the future, if any product is approved, customers would shift to hospitals, oncology specialists and payers, but that is not yet the case. The company’s current customer base is therefore concentrated, partnership-driven and highly dependent on clinical progress.

- **Strategic pharmaceutical collaborators** (primary) — Large pharma partners that pay upfronts, milestones, option fees and fund joint development to access Arcus’s pipeline and share risk.
- **Clinical development partners** (primary) — Companies participating in combination trials and joint studies to evaluate Arcus assets in specific tumor settings.
- **Future oncology treatment buyers** (emerging) — Hospitals, oncologists and reimbursing payers that would buy approved therapies if Arcus successfully commercializes a product.

- Gilead as the primary collaboration partner funding key oncology programs
- Taiho as a partner with option rights to the CD39 program
- AstraZeneca as a clinical collaboration partner on combination studies
- Abmuno as the original licensor of the anti-TIGIT antibody rights
- Future oncology prescribers and payers if any asset reaches approval

## Geography

Arcus is headquartered in Hayward, California and is organized as a U.S.-based biotechnology company. The reports do not disclose a meaningful country-by-country revenue mix because the company has not generated product sales and collaboration revenue is not broken out by geography in the excerpts provided. Its operating footprint is therefore centered in the United States, while clinical development and supply-chain activity can extend into multiple trial countries through CROs, investigators and third-party manufacturers. The company also references clinical supply constraints in certain countries where trials are conducted, showing that development execution has an international operational footprint even without commercial sales. Geography matters mainly through trial enrollment, manufacturing logistics and regulatory exposure rather than through end-market sales today.

- Headquartered in Hayward, California, United States
- No disclosed country-level revenue mix in the provided excerpts
- Clinical trials and supply chains extend into multiple countries
- Third-party manufacturing and CRO activity create cross-border execution risk
- Commercial geography is not yet established because no product sales exist

## Strategy

Arcus’s strategy is to advance a differentiated oncology pipeline through late-stage clinical development while using partnerships to share cost, scientific risk and commercialization optionality. The company is prioritizing key assets such as domvanalimab, quemliclustat, etrumadenant and casdatifan in combination regimens where it believes it can create clinically meaningful differentiation. It is also using collaborations with Gilead, Taiho and AstraZeneca to expand trial breadth and preserve capital. Because it has no product revenue, capital discipline and access to external funding are central to strategy, including equity, debt and collaboration proceeds. The company’s long-term objective is to convert its pipeline into approved products or valuable partnered assets, but near-term value creation depends on clinical readouts and regulatory progress.

- **Progress key oncology programs through clinical milestones** (short-term) — Clinical success is the main driver of valuation and future partnering/commercial potential.
- **Deepen and monetize strategic collaborations** (medium-term) — Partnerships provide non-dilutive funding, external validation and shared development capacity.
- **Maintain liquidity and development flexibility** (short-term) — The company must fund substantial R&D before any product revenue is available.

- Advance late-stage oncology assets through pivotal and combination trials
- Use collaborations to share development cost and scientific risk
- Preserve capital by outsourcing manufacturing and relying on third parties
- Maintain optionality through license, option and partnership structures
- Fund operations with equity, debt and collaboration cash until commercialization

## Risks

Arcus faces the core biotechnology risk that its investigational products may fail in clinical development, receive delayed regulatory approval, or never reach commercialization. Because its revenue is concentrated in collaboration accounting rather than product sales, changes in partner behavior, milestone timing or termination of programs can materially affect reported revenue and liquidity. The company also depends on third-party manufacturers and CROs, so supply disruptions, quality failures or regulatory non-compliance could delay trials or force program pauses. Competitive pressure is intense in oncology immunotherapy, where larger companies and better-funded peers may reach the market sooner or produce superior data. More generally, biotech companies like Arcus are exposed to financing risk, IP risk, reimbursement risk and rapid changes in standard of care that can make a promising asset commercially obsolete before approval.

- **Failure to obtain or delay in obtaining regulatory approval** [critical] — The company’s value depends on investigational products reaching approval; delays materially harm the business.
- **Clinical development and trial enrollment setbacks** [high] — Trial outcomes, enrollment speed and comparator drug availability directly affect development timelines and costs.
- **Supply chain and third-party manufacturing disruption** [high] — Arcus relies on single-source or external manufacturers for API, drug product and trial materials.
- **Competitive pressure in oncology immunotherapy** [high] — Larger peers may launch better or faster therapies, reducing Arcus’s commercial opportunity.
- **Dependence on collaboration revenue and partner actions** [high] — Revenue recognition and cash inflows depend on partner funding, milestones and continued development.

- Clinical failure or delay could eliminate value in key pipeline assets
- Partner decisions can change revenue timing and program economics
- Third-party manufacturing and supply chain dependence can disrupt trials
- Intense oncology competition may outpace Arcus on efficacy, safety or speed
- Regulatory requirements may become more demanding as classes mature
- Need for external financing creates dilution and liquidity risk

## Accounting

Arcus’s accounting is dominated by collaboration revenue recognition rather than product sales, so the timing of partner payments and performance obligations can create large quarter-to-quarter swings. The company recognizes license and development services revenue over time or at delivery based on estimates of standalone selling price and percentage of completion, which requires significant management judgment. The 2025 quarter showed a sharp revenue decline versus the prior year because the prior period included a cumulative catch-up adjustment tied to the Gilead collaboration amendment, illustrating how contract revisions can materially move revenue. Deferred revenue is also important: the company disclosed $210 million of deferred revenue related to Gilead upfront payments, much of which could be recognized if development stops or approval is not achieved. Because Arcus has no product sales, investors should focus on how collaboration accounting, milestone timing and impairment charges affect reported results and comparability across periods.

- **Revenue recognition for collaboration agreements** — Large quarter-to-quarter swings and potential cumulative catch-up adjustments
- **Deferred revenue related to Gilead upfront payments** — Future revenue timing and magnitude
- **Standalone selling price estimates** — Revenue allocation across periods
- **Impairment of long-lived assets** — Operating expense volatility

- Revenue is mainly collaboration and license revenue, not product sales
- Over-time revenue recognition depends on estimated progress toward obligations
- Standalone selling price judgments affect allocation of upfront payments
- Contract amendments can create large cumulative catch-up adjustments
- Deferred revenue balances can reverse if programs stop or are terminated
- R&D and long development cycles create volatile quarterly comparability

---

*Last updated: 2026-08-11T04:46:21.290452+00:00*